SERTAD1 and gastric cancer: And, lower expression of SERTAD1 predicted significant (n = 655, Logrank test p = 0.00011) enhanced overall survival of patients with ovarian cancer while there is no significant (n = 631, Logrank test p = 0.1866) differences observed in gastric cancer [29].